Ceftolozane/tazobactam
To view the entire topic, please log in or purchase a subscription.
Pediatrics Central™ is an all-in-one application that puts valuable medical information, via your mobile device or the web, in the hands of clinicians treating infants, children, and adolescents. Explore these free sample topics:
-- The first section of this topic is shown below --
INDICATIONS
FDA
- Ceftolozane/tazobactam is currently on manufacturer backorder. Per communication from Merck, the drug is not expected to be released until early 2022.
- Alternative therapies for MDR Pseudomonas aeruginosashould be considered.
- Complicated intra-abdominal infections (cIAI), used in combination with metronidazole
- Complicated urinary tract infections (cUTI), including pyelonephritis
- Hospital-acquired bacterial and ventilator-associated pneumonia (VAP)
Note: FDA indications for age ≥ 18 yrs
NON-FDA APPROVED USES
- Pseudomonas aeruginosa infections (including some MDR isolates, limited data[6])
-- To view the remaining sections of this topic, please log in or purchase a subscription --
INDICATIONS
FDA
- Ceftolozane/tazobactam is currently on manufacturer backorder. Per communication from Merck, the drug is not expected to be released until early 2022.
- Alternative therapies for MDR Pseudomonas aeruginosashould be considered.
- Complicated intra-abdominal infections (cIAI), used in combination with metronidazole
- Complicated urinary tract infections (cUTI), including pyelonephritis
- Hospital-acquired bacterial and ventilator-associated pneumonia (VAP)
Note: FDA indications for age ≥ 18 yrs
NON-FDA APPROVED USES
- Pseudomonas aeruginosa infections (including some MDR isolates, limited data[6])
There's more to see -- the rest of this topic is available only to subscribers.